Spanish media reports on a promising direction in Alzheimer's disease research. Scientists have begun testing a modification of CAR-T therapy, previously used in oncology, in the fight against neurodegeneration in animal models. Preliminary experiments on mice have shown that genetically modified T cells can target and eliminate beta-amyloid protein deposits, which are considered a key pathological factor in the development of dementia. The therapy, though still in the preclinical phase, could potentially counteract the progression of the disease, rather than just alleviate its symptoms. Researchers emphasize the need for further, long-term safety and efficacy tests before human trials can be considered.
Breakthrough Application of CAR-T
CAR-T therapy, successfully used in treating some blood cancers, is being tested for the first time in the context of Alzheimer's disease. It involves genetically modifying a patient's own T cells so that they recognize and destroy target cells, which in this case are intended to be beta-amyloid deposits.
Promising Results in Mice
Preliminary experiments conducted on a mouse model of Alzheimer's disease showed that the therapy effectively reduces the level of pathological amyloid protein in the brain. This suggests a potential ability to modify the underlying disease process, not just provide symptomatic treatment for dementia.
Challenges Before Implementation
Despite optimistic results, the path to potential human application is long. Confirming the therapy's safety in the nervous system and investigating long-term effects will be crucial. Scientists must also check whether amyloid reduction translates into a clear improvement in cognitive functions.
A Paradigm Shift in Treatment
The research represents a broader trend of seeking immunomodulatory therapeutic methods in neurology. If successful, it could pave the way for causal treatment of other neurodegenerative diseases, such as Parkinson's disease, where abnormal proteins also play a key role.
Spanish news portals report on a potential breakthrough in Alzheimer's disease research. Scientists have begun testing an adaptation of CAR-T therapy, known for its revolutionary successes in hematological oncology, as a tool to fight dementia. Preliminary results from preclinical studies in mice, published in a prestigious scientific journal, indicate that a patient's genetically engineered T cells can be "taught" to recognize and destroy toxic beta-amyloid protein deposits in the brain. This is particularly significant because the accumulation of this protein is considered one of the main causes of neurodegeneration in Alzheimer's. To date, pharmacological therapies have mainly focused on alleviating disease symptoms or slowing its progression to a limited extent, rather than removing its cause. The new approach has the potential to change this paradigm. Alzheimer's disease, first described in 1906 by Alois Alzheimer, is the most common cause of dementia worldwide. For decades, research has focused on the amyloid and tau hypotheses of disease formation, with main therapeutic efforts directed at creating monoclonal antibodies. The first drugs of this type, such as aducanumab or lecanemab, received controversial regulatory approval in recent years; however, their efficacy is moderate, and their action focuses on reducing existing deposits. The mechanism of action of the new therapy involves collecting T cells from the patient, genetically modifying them in the laboratory using a viral vector to express a chimeric antigen receptor (CAR), and then reinfusing them into the body. This receptor is designed to specifically bind to beta-amyloid. In theory, the modified immune cells could migrate across the blood-brain barrier and conduct a "clean-up" of pathological proteins. „La terapia CAR-T contra el alzhéimer es un enfoque pionero y audaz. Si se confirma su seguridad, podría revolucionar la neurología como lo ha hecho con la oncología.” — Gloria Álvarez, science editor Despite promising data from the animal model, researchers emphasize serious challenges. The main one is safety: an excessive or uncontrolled immune response in the delicate brain environment could cause serious side effects, such as neurotoxicity or swelling. Furthermore, it must be confirmed that amyloid reduction actually translates into a significant and lasting improvement in cognitive functions, not just a change in biomarkers. The next step will be long-term studies on larger animals to assess potential risks. Even in an optimistic scenario, clinical trials involving humans are several years away. „La inmunoterapia que está curando el cáncer se atreve con el alzhéimer” (ABC) — The title suggests that immunotherapy "cures" cancer, which is a significant oversimplification. CAR-T therapy is highly effective in some types of blood cancers, but not all, and the term "cures" may mislead about its universal efficacy. Furthermore, the use of the word "dares" (atreve) gives the report an unnecessarily sensationalist tone. This research fits into a broader trend of seeking applications for CAR-T technology beyond oncology. Work is underway on its use in autoimmune diseases, such as lupus or scleroderma, as well as in combating viral infections like HIV. Success in the Alzheimer's field could thus open the door to a completely new class of therapies for many previously incurable chronic conditions. At the same time, questions remain about the cost of such treatment – CAR-T therapy in oncology is one of the most expensive available procedures – and the logistics of its implementation, which requires specialized centers. Despite these challenges, the concept itself represents fresh and potentially groundbreaking thinking about the therapy of neurodegenerative diseases, offering hope to millions of patients and their families worldwide.
Mentioned People
- Gloria Álvarez — science editor of a Spanish portal